A Spanish research team achieved complete and lasting regression of pancreatic tumors in mice.
The triple therapy targets three key points in the KRAS oncogene molecular pathway.
This approach overcomes resistance that typically arises when targeting a single point in the pathway. Why this matters: Pancreatic cancer is often diagnosed late and is resistant to many treatments, making this a significant step forward.
The therapy combined an experimental KRAS inhibitor, a lung cancer drug, and a protein degrader, showing no significant side effects in animal models.
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is notoriously difficult to treat. The study, led by cancer biologist Mariano Barbacid, tackled the issue of treatment resistance by simultaneously blocking multiple pathways that cancer cells use to survive. The triple therapy consisted of:
Daraxonrasib: Blocks the main KRAS signal.
Afatinib: Shuts down EGFR and HER2 pathways.
SD36: Disables STAT3, a backup survival system.
The results showed complete tumor shrinkage with no recurrence in mice, suggesting a potential turning point in treating this lethal cancer. While still in early stages, the findings pave the way for human clinical trials.
Q: What makes pancreatic cancer so difficult to treat?
It is often diagnosed late, spreads quickly, and develops resistance to treatments.
Q: What is the significance of this study?
It demonstrates a novel approach to overcome treatment resistance in pancreatic cancer, leading to complete tumor regression in mice.
Pancreatic cancer treatment may be revolutionized by triple combination therapy.
The study highlights the importance of targeting multiple pathways to prevent treatment resistance.
Clinical trials in humans are the next step to validate these findings.
Do you think this new approach will translate to successful human trials? Share this article with others who need to stay ahead of this trend!
Recent developments in Amyotrophic Lateral Sclerosis (ALS) research offer a glimmer of hope. News surrounding a potential treatment from Neu...
Researchers at the Otto von Guericke University Magdeburg, Germany, have announced a significant development in cancer research. They have s...
A groundbreaking clinical trial in Newcastle is exploring a new therapy that researchers hope could effectively "switch off" rheumatoid arth...
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer